
Noxopharm Limited
ASX:NOX.AX
Overview | Financials
Company Name | Noxopharm Limited |
Symbol | NOX.AX |
Currency | AUD |
Price | 0.077 |
Market Cap | 22,502,322 |
Dividend Yield | 0% |
52-week-range | 0.058 - 0.15 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gisela Mautner |
Website | https://www.noxopharm.com |
An error occurred while fetching data.
About Noxopharm Limited
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD